COMMUNIQUÉS West-GlobeNewswire

Corvus Pharmaceuticals Announces Publication of Preclinical Study Results Demonstrating CPI-444 Antitumor Activity as Monotherapy and in Combination with Anti-PD-1 Therapy in Cancer Immunology, Immunotherapy
28/06/2018
Research elucidated novel mechanisms of CPI-444 indicating broad effects on several checkpoints BURLINGAME, Calif., June 28, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage [...]
International Endeavors Offers Equipment to Licensed Marijuana Growers
28/06/2018
TEMECULA, Calif., June 28, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- International Endeavors Corporation (OTC:IDVV) offers an innovative cooperative program for licensed marijuana growers to make use of the Off Grid [...]
GTX Corp Launches 2 New GPS Trackers for Kids SmartSole Now Available in Size Small
28/06/2018
LOS ANGELES, June 28, 2018 (GLOBE NEWSWIRE) -- GTX Corp (OTCBB:GTXO), an IoT platform and global provider of GPS tracking and monitoring wearable and wandering assistive technology, announces today the launch of the GPS [...]
Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients
28/06/2018
Minimal Residual Disease is increasingly recognized as a primary driver of high AML relapse rate highlighting need for improved consolidation therapies Webcast to be held on July 10, 2018 at 8:00 AM ET to discuss [...]
Retrotope Receives FDA Clearance to Commence RT001 Phase 2/3 Clinical Trial in Patients with Infantile Neuroaxonal Dystrophy (INAD)
28/06/2018
Patient enrollment anticipated to start in July 2018 LOS ALTOS, Calif., June 28, 2018 (GLOBE NEWSWIRE) -- Retrotope announced today that the U.S. Food and Drug Administration (FDA) has granted the company approval to [...]
BRACAnalysis® CDx Identifies Patients Who Respond to Lynparza® in SOLO-1 Study
28/06/2018
SALT LAKE CITY, June 28, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, today announced that the Company’s BRACAnalysis ® CDx test identified responders to [...]
Amfora Unveils Broad Initiative to Develop Crops with Enhanced Protein Content for Food and Feed
28/06/2018
SAN FRANCISCO, June 28, 2018 (GLOBE NEWSWIRE) -- Amfora Inc., a biotechnology company committed to improving the nutritional content of food and feed crops, today unveiled a major new program to develop crops with [...]
scPharmaceuticals Appoints Frederick Hudson to Board of Directors
28/06/2018
BURLINGTON, Mass., June 28, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of [...]
CLS Holdings USA Closes Acquisition of Oasis Cannabis
28/06/2018
Enters the Legalized Cannabis Market in Las Vegas, NV Currently Generating Approximately $850,000 per Month in Revenue LAS VEGAS, June 28, 2018 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB:CLSH) “CLS,” a [...]
Cellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 Trial
28/06/2018
Response rate in cohort exceeded pre-specified value MADISON, Wis., June 28, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, [...]
Flatiron Health CMO/CSO Joins CareDx Board of Directors
28/06/2018
Amy Abernethy adds clinical expertise and patient data insights to the CareDx Board BRISBANE, Calif., June 28, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the [...]
Zafgen Announces Pricing of Offering of Common Stock
28/06/2018
BOSTON, June 28, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by [...]
Cocrystal Pharma Commences Enrollment and Initiates Patient Dosing in Phase 2a Study Evaluating CC-31244 for the Treatment of HCV
28/06/2018
- Topline results from Phase 2a study expected to be announced before year end - ATLANTA, GA and BOTHELL, WA, June 28, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a [...]
Repligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand
28/06/2018
WALTHAM, Mass., June 28, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced it has entered into an agreement with [...]
Kura Oncology Announces Pricing of $67 Million Public Offering of Common Stock
28/06/2018
SAN DIEGO, June 28, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the pricing of [...]
MPI: Orphan Drug designation on Oncology Venture's dovitinib for Adenoid Cystic Carcinoma
28/06/2018
Hoersholm, Denmark, June 28, 2018 -Medical Prognosis Institute A/S (MPI:ST) and Oncology Venture AB (OV:ST) announces that the Office of Orphan Products Development at the FDA has transferred the Dovitinib Orphan drug [...]
Kymab Announces Agreement to Evaluate KY1044, its Novel Antibody Targeting ICOS, and Anti-PD-L1 Immunotherapy for testing in Multiple Solid Tumors
28/06/2018
Kymab Announces Agreement to Evaluate KY1044, its Novel Antibody Targeting ICOS, and Anti-PD-L1 Immunotherapy for testing in Multiple Solid Tumors Phase I/II studies will evaluate Kymab’s lead investigational therapy [...]
Helius Medical Technologies, Inc. Announces MRI Confirmatory Evidence of Neuroplastic Change after Investigational PoNS™ Treatment Presented at the 2018 Joint Annual Meeting ISMRM – ESMRMB in Paris, France
28/06/2018
NEWTOWN, Pa., June 28, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced today that an [...]
Arsanis Provides Update Following Completion of Planned Interim Analysis of Phase 2 Clinical Trial of ASN100
28/06/2018
Trial Unlikely to Meet Primary Efficacy Endpoint; Arsanis to Cease Trial Enrollment and Evaluate Complete Clinical Trial Dataset Arsanis to Continue Focus on Development of ASN500 for Prevention of RSV Infection WALTHAM [...]

Pages